Actient Pharmaceuticals completes transaction to license; acquire six pharmaceutical products from UCB

May 09, 2017

"The transaction to license and acquire these products is a key first step in achieving our objective of building a leading specialty pharmaceutical company," added GTCR Principal, Dean Mihas. "The Actient management team led by Ed Fiorentino has an impressive track record of establishing and growing businesses and we're excited to be a partner in this transaction and are committed to providing the resources to further Actient's growth."

Prior to partnering with GTCR, Ed Fiorentino was a corporate officer and 22-year veteran of Abbott Laboratories (NYSE:ABT). His senior-level management experience at Abbott included Corporate Vice President of Pharmaceutical Commercial Operations, where he was responsible for all U.S. sales, marketing and new product planning. He also served as Senior Vice President and President of Abbott Diabetes Care, leading Abbott's global device business in this area. Most recently, Ed was Executive Vice President of TAP Pharmaceutical, an Abbott joint venture with Takeda Pharmaceutical.

Legal counsel for the transaction included Kirkland & Ellis LLP and Hogan Lovells, advising Actient and GTCR. Torreya Partners LLC served as financial advisor to GTCR and Actient. GE Capital and LCB Credit Partners provided the initial debt financing commitment in support of the acquisition.

SOURCE Actient Pharmaceuticals